NASDAQ:NVLN Novelion Therapeutics (NVLN) Stock Price, News & Analysis → Discover How to Turn $10,000 into $1 Million (From Paradigm Press) (Ad) Free NVLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.68▼$0.7052-Week Range N/AVolume26,947 shsAverage Volume190,529 shsMarket Capitalization$13.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Novelion Therapeutics alerts: Email Address Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About Novelion Therapeutics Stock (NASDAQ:NVLN)Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Read More Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. NVLN Stock News HeadlinesJune 2, 2023 | finance.yahoo.comCYTO - Altamira Therapeutics Ltd.See More Headlines Receive NVLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2019Today6/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVLN CUSIPN/A CIK827809 Webwww.novelion.com Phone617-500-7867FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,330,000.00 Net Margins-79.43% Pretax MarginN/A Return on EquityN/A Return on Assets-26.13% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.21 Sales & Book Value Annual Sales$130.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($4.69) per share Price / BookN/AMiscellaneous Outstanding Shares19,619,000Free FloatN/AMarket Cap$13.77 million OptionableOptionable Beta2.12 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Benjamin S. Harshbarger (Age 50)Interim CEO, Gen. Counsel & Corp. Sec. Mr. Michael D. Price (Age 61)Exec. VP & CFO Mr. Roger W. Louis (Age 63)Global Chief Compliance Officer and Head of R&D Ms. Barbara Y. Chan (Age 55)VP & Chief Accounting Officer Ms. Amanda MurphyDirector of Investor Relations & Corp. CommunicationsKey CompetitorsvTv TherapeuticsNASDAQ:VTVTBioLineRxNASDAQ:BLRXImmix BiopharmaNASDAQ:IMMXBioXcel TherapeuticsNASDAQ:BTAICleneNASDAQ:CLNNView All Competitors NVLN Stock Analysis - Frequently Asked Questions How were Novelion Therapeutics' earnings last quarter? Novelion Therapeutics Inc. (NASDAQ:NVLN) released its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to the consensus estimate of $40.90 million. What other stocks do shareholders of Novelion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Amicus Therapeutics (FOLD), Applied Genetic Technologies (AGTC), Advanced Micro Devices (AMD), Biocept (BIOC), Karyopharm Therapeutics (KPTI), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and Actinium Pharmaceuticals (ATNM). This page (NASDAQ:NVLN) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novelion Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novelion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.